Recent Comments

Comment RSS

Alopecia News and Research RSS Feed - Alopecia News and Research

Alopecia is the lack or loss of hair from areas of the body where hair is usually found. Alopecia can be a side effect of some cancer treatments.

NeoPharm presents LE-DT Phase I data at the AACR conference

18. November 2009 04:30
NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA. [More]

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

17. November 2009 04:14
A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao. [More]

Tips for treating age-related dermatologic concerns

11. November 2009 02:58
Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike. [More]

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

10. November 2009 07:09
The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer. [More]

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

6. November 2009 07:38
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. [More]

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

23. October 2009 03:42
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. [More]

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

14. October 2009 09:16
ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed. [More]

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

12. October 2009 09:07
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California. [More]

The CE Marked HairDX Genetic Test for Hair Loss launched in Europe

8. October 2009 04:51
The HairDX Genetic Test for Hair Loss, the world’s first genetic baldness (Androgenetic Alopecia) test, is now available as a CE Marked product under the European In Vitro Diagnostic Directive. [More]

Posted in: Device / Technology News

Tags: , , , , , , ,

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

7. October 2009 00:33
R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness). [More]

Posted in: Men's Health News | Drug Trial News

Tags: , , , ,

Reportlinker's medical review criteria guidelines for managing care

30. September 2009 08:03
Reportlinker Adds Medical Review Criteria Guidelines for Managing Care (8th ed. - 2009) [More]

Posted in: Healthcare News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Symposium on genetics of psoriasis and psoriatic arthritis to be held

24. September 2009 06:36
A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany. [More]

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

23. September 2009 07:13
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer. [More]

Advanced Hair Studio to introduce genetic baldness tests in Australia

23. September 2009 05:16
Men and women in Australia now have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC. (www.hairdx.com) [More]

Posted in: Medical Science News

Tags: , , , , ,

Bayer's regorafenib showed 50% stabilization rate in RCC patients

22. September 2009 03:40
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.